TATVA CHINTAN PHARMA CHEM LIMITED Financials Tatva Chintan Pharma Chem Limited Bombay S.E.
Equities
TATVA
INE0GK401011
Specialty Chemicals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,139 INR | +0.58% |
|
+3.42% | -28.90% |
| 03/05 | Transcript : Tatva Chintan Pharma Chem Limited, Q4 2024 Earnings Call, May 03, 2024 | |
| 03/05 | Tatva Chintan Pharma Chem Limited Recommends Final Dividend for the Financial Year 2023-2024 | CI |
Valuation
| Fiscal Period: Maart | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 51,166 | 36,995 | 26,511 | - | - |
| Enterprise Value (EV) 1 | 50,595 | 36,995 | 25,231 | 26,511 | 26,511 |
| P/E ratio | 51.8 x | 81.3 x | 81.3 x | 38.2 x | 22.5 x |
| Yield | 0.09% | - | 0.14% | 0.3% | 0.79% |
| Capitalization / Revenue | 11.8 x | 8.73 x | 6.41 x | 5.07 x | 3.34 x |
| EV / Revenue | 11.8 x | 8.73 x | 6.41 x | 5.07 x | 3.34 x |
| EV / EBITDA | 47.3 x | 61.1 x | 37 x | 27.1 x | 15.9 x |
| EV / FCF | -74.4 x | -21.1 x | 38 x | -83.1 x | 482 x |
| FCF Yield | -1.34% | -4.74% | 2.63% | -1.2% | 0.21% |
| Price to Book | 10.8 x | 7.19 x | 3.52 x | 3.4 x | 3.16 x |
| Nbr of stocks (in thousands) | 22,165 | 22,165 | 23,392 | - | - |
| Reference price 2 | 2,308 | 1,669 | 1,133 | 1,133 | 1,133 |
| Announcement Date | 25/04/22 | 05/05/23 | 03/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 4,336 | 4,236 | 3,935 | 5,224 | 7,946 |
| EBITDA 1 | - | 1,082 | 605.8 | 682 | 978 | 1,672 |
| EBIT 1 | - | 1,001 | 510.3 | 425.9 | 659 | 1,312 |
| Operating Margin | - | 23.07% | 12.05% | 10.82% | 12.61% | 16.52% |
| Earnings before Tax (EBT) 1 | - | 1,041 | 447.8 | 435.7 | 685 | 1,324 |
| Net income 1 | 522.6 | 958.7 | 454.9 | 303.5 | 513 | 991.5 |
| Net margin | - | 22.11% | 10.74% | 7.71% | 9.82% | 12.48% |
| EPS 2 | - | 44.59 | 20.52 | 13.26 | 29.63 | 50.27 |
| Free Cash Flow 1 | - | -687.8 | -1,753 | 698 | -319 | 55 |
| FCF margin | - | -15.86% | -41.39% | 17.19% | -6.11% | 0.69% |
| FCF Conversion (EBITDA) | - | - | - | 91.12% | - | 3.29% |
| FCF Conversion (Net income) | - | - | - | 207.12% | - | 5.55% |
| Dividend per Share 2 | - | 2.000 | - | 1.600 | 3.400 | 9.000 |
| Announcement Date | 06/09/21 | 25/04/22 | 05/05/23 | 03/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Maart | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,236 | 1,047 | 985.3 | 884 | 900.9 | 1,206 | 1,245 | 1,144 | 1,155 | 1,064 | 998.2 |
| EBITDA 1 | 358.9 | 238.1 | 219.5 | 152.2 | 111.8 | 179.1 | 162.7 | 213.4 | 216 | 219.5 | 161.5 |
| EBIT 1 | - | 217.3 | 198 | 128.8 | 88.69 | 155.3 | - | 153.3 | 153 | 158 | 156 |
| Operating Margin | - | 20.76% | 20.1% | 14.57% | 9.84% | 12.88% | - | 13.41% | 13.25% | 14.85% | 15.63% |
| Earnings before Tax (EBT) | - | - | 189.8 | 137 | 90.58 | 142.2 | - | - | 139.5 | 133 | 132 |
| Net income 1 | - | - | 175.1 | 97.97 | 71.12 | 116.2 | 169.5 | 95.04 | 104 | 105.5 | 76.25 |
| Net margin | - | - | 17.77% | 11.08% | 7.89% | 9.64% | 13.62% | 8.31% | 9% | 9.92% | 7.64% |
| EPS | - | - | - | - | 3.210 | - | - | - | 4.450 | 5.500 | 4.100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 23/10/21 | 17/01/22 | 25/04/22 | 25/07/22 | 04/11/22 | 25/01/23 | 05/05/23 | 04/08/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: Maart | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 570 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -688 | -1,753 | 698 | -319 | 55 |
| ROE (net income / shareholders' equity) | - | 30% | 9.94% | 5.6% | 6.8% | 13.2% |
| ROA (Net income/ Total Assets) | - | 19.7% | 6.94% | 3.3% | 7.8% | 11.4% |
| Assets 1 | - | 4,866 | 6,555 | 10,212 | 6,577 | 8,697 |
| Book Value Per Share 2 | - | 213.0 | 232.0 | 322.0 | 334.0 | 359.0 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 892 | 2,031 | 500 | 850 | 1,100 |
| Capex / Sales | - | 20.56% | 47.95% | 12.31% | 16.27% | 13.84% |
| Announcement Date | 06/09/21 | 25/04/22 | 05/05/23 | 03/05/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1,133
INR
Average target price
1,608
INR
Spread / Average Target
+41.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.91% | 6.73TCr | |
| -6.54% | 4.53TCr | |
| +23.68% | 4.37TCr | |
| +37.87% | 2.81TCr | |
| +9.03% | 1.92TCr | |
| +15.11% | 1.72TCr | |
| -26.04% | 1.46TCr | |
| -13.27% | 1.45TCr | |
| -29.84% | 1.16TCr |
- Stock Market
- Equities
- TATVA Stock
- TATVA Stock
- Financials Tatva Chintan Pharma Chem Limited
